Phase 1 Neovascular Age-related Macular Degeneration Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Intra-IMMUSG Pte Ltd15 enrolled1 locationNCT07547228
Recruiting
Phase 1Phase 2
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-Related Macular Degeneration (nAMD)
Alcon Research140 enrolled42 locationsNCT05769153
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Sanofi66 enrolled18 locationsNCT06660667
Recruiting
Phase 1Phase 2
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Skyline Therapeutics (US) Inc.68 enrolled9 locationsNCT05986864
Recruiting
Phase 1
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Youxin Chen12 enrolled3 locationsNCT06213038
Recruiting
Phase 1Phase 2
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Shanghai Refreshgene Technology Co., Ltd.48 enrolled1 locationNCT06141460
Recruiting
Phase 1Phase 2
Gene Therapy(FT-003) for Wet AMD
Neovascular Age-related Macular Degeneration
Frontera Therapeutics78 enrolled1 locationNCT06492863